Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
- TRADE NAME: Viekira XR (AbbVie)
- INDICATIONS: Genotype 1a chronic hepatitis C virus with or without cirrhosis; genotype 1b chronic hepatitis C virus with or without cirrhosis in combination with ribavirin
- CLASS: CYP3A4 inhibitor (ritonavir), Direct-acting antiviral, Hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor (dasabuvir), Hepatitis C virus NS3/4A protease inhibitor (paritaprevir), Hepatitis C virus NS5A inhibitor (ombitasvir)
- HALF-LIFE: 6 hours (dasabuvir); 21–25 hours (ombitasvir); 6 hours (paritaprevir); 4 hours (ritonavir)
FDA APPROVAL DATE: 07/22/2016
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfuzosin, Carbamazepine, Cisapride, Copanlisib, Dihydroergotamine, Dronedarone, Efavirenz, Ergotamine, Ethinyl estradiol-containing medications, Gemfibrozil, Lovastatin, Lurasidone, Methylergonovine, Midazolam, Midostaurin, Neratinib, Phenobarbital, Phenytoin, Pimozide, Ranolazine, Rifampin, Sildenafil, Simvastatin, St John's Wort, Triazolam
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin
Contra-indicated in patients with moderate to severe hepatic impairment.
Viekira XR is a combined ombitasvir, paritaprevir, ritonavir and dasabuvir extended release tablet.
In May 2018, the FDA announced the discontinuation of Viekira XR with an estimated product availability through until January 1, 2019.
See also separate entries for Ombitasvir/Paritaprevir/Ritonavir (co-packaged with Dasabuvir as Viekira Pak) and Ribavirin.
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
